Abstract

Legionella pneumophila, which is the causative organism of Legionnaires disease, translocates numerous effector proteins into the host cell cytosol by a type IV secretion system during infection. Among the most potent effector proteins of Legionella are glucosyltransferases (Lgt’s), which selectively modify eukaryotic elongation factor (eEF) 1A at Ser-53 in the GTP binding domain. Glucosylation results in inhibition of protein synthesis. Here we show that in vitro glucosylation of yeast and mouse eEF1A by Lgt3 in the presence of the factors Phe-tRNAPhe and GTP was enhanced 150 and 590-fold, respectively. The glucosylation of eEF1A catalyzed by Lgt1 and 2 was increased about 70-fold. By comparison of uncharged tRNA with two distinct aminoacyl-tRNAs (His-tRNAHis and Phe-tRNAPhe) we could show that aminoacylation is crucial for Lgt-catalyzed glucosylation. Aminoacyl-tRNA had no effect on the enzymatic properties of Lgt’s and did not enhance the glucosylation rate of eEF1A truncation mutants, consisting of the GTPase domain only or of a 5 kDa peptide covering Ser-53 of eEF1A. Furthermore, binding of aminoacyl-tRNA to eEF1A was not altered by glucosylation. Taken together, our data suggest that the ternary complex, consisting of eEF1A, aminoacyl-tRNA and GTP, is the bona fide substrate for Lgt’s.

Introduction

Legionella pneumophila is responsible for severe pneumonia referred to as Legionnaires disease [1]. The bacterium lives ubiquitously in aquatic environments, where it invades and replicates within protozoa [2]. Infection occurs predominantly due to inhalation of contaminated water sources [3]. After entering phagocytic host cells such as alveolar macrophages, Legionella survives and replicates intracellularly [4]. To this end, Legionella produces a plethora of effector proteins, which are injected into the host cell cytosol via a type IVb secretion system (Dot/Icm system) [5–7] to subvert the phagosome into a specialized compartment known as “Legionella containing vacuole” (LCV) [8–10]. The LCV fails to enter the lysosomal degradative pathway and rather generates an intracellular environment where Legionella can replicate extensively. Bioinformatics, genetic and reporter-fusion screens for Dot/Icm effector proteins of Legionella identified >300 candidates [8,11–15]. Only a few were biochemically validated and even less were characterized at the molecular level [8]. Some of these effectors are known to target distinct regulatory host cell factors such as GTPases or ATPases [16–23] in order to transform the host cell into a replication permissive environment [8]. A number of effectors interact with vesicles and influence their maturation by altering phosphoinositides involved in trafficking and regulation [24]. However, most effector targets remain elusive.

Among the best-studied effectors are members of the Legionella glucosyltransferase family (Lgt) [25,26]. Pathogenic strains of L. pneumophila possess up to three Lgt isoforms (Lgt1-3) [27]. Unfortunately, data describing lgt-deletion strains concerning intracellular replication or phenotypic alteration are lacking. Recently, the crystal structure of Lgt1 was solved independently by two groups [28,29]. Lgt1 exhibits a typical glucosyltransferase GT-A type of fold with a central UDP-glucose binding domain, sharing significant similarity with the glucosyltransferase domain of Clostridium difficile toxins A and B [26,30]. Inside the host cell, Lgt’s modify eukaryotic elongation factor 1A (eEF1A) by mono-O-glucosylation and thereby inhibit protein synthesis. It has been suggested that inhibition of protein synthesis of host cells by Lgt’s induces cell death. This might be important at the end of the proliferation cycle of Legionella supporting the release of the pathogen [31]. However, it cannot be excluded that inhibition of protein synthesis is necessary for establishment of the optimal environment for Legionella replication. Moreover, protein synthesis
inhibition by L. pneumophila may have major consequences for the innate immune response of the host [32].

Eukaryotic EF1A, one of the most abundant proteins in the cytosol of the eukaryotic cell, is glucosylated at Ser-53, which is located on a protruding region including helices A* and A’ in the GTPase domain [31]. This region is lacking in the prokaryotic homolog of eEF1A, EF-Tu and therefore, Legionella is protected from its own toxic effector. The canonical function of eEF1A is the delivery of aminoacyl-tRNAs to the ribosome for protein synthesis. eEF1A belongs to the superfamily of the GTP binding proteins, which can bind and hydrolyze GTP. Upon GTP-hydrolysis, the conformation of the eEF1A switches between an active (GTP-bound) and inactive (GDP-bound) state. The eEF1A cycle begins with the GDP/GTP exchange catalyzed by the guanine nucleotide exchange factor eEF1B. In the GTP-bound form eEF1A has high affinity for aa-tRNA and forms a stable ternary complex [33]. The ternary complex protects aa-tRNA from RNases and spontaneous hydrolysis and facilitates delivery of aa-tRNA to the decoding site of the ribosome (A site) [33]. eEF1B mediates the accurate interaction of aa-tRNA anticonodon with the codon of the mRNA in the A site of the ribosome. Codon-anticodon recognition triggers GTP-hydrolysis by eEF1A, which might affect the affinity for eEF1A to aminoacyl-tRNA. Consequently eEF1A dissociates and enters into a new elongation cycle. Apart from the role in protein synthesis, several non-canonical functions of eEF1A have been described (e.g. nuclear export activities, turnover of misfolded proteins, actin cytoskeleton organization and cellular stress responses [34,35]).

Recently, it was shown that Lgt’s are able to glucosylate a decapeptide (50GKGSFKYAWV59) covering the loop formed by helices A* and A’ of eEF1A [36]. Interestingly, glucosylation of this decapeptide was far more efficient than the modification of helices A* and A’ of eEF1A [36]. Interestingly, glucosylation (Fig. 2, lane 2) and also Phe-tRNA Phe in the ternary complex of yeast eEF1A (Fig. 2B). These results strongly suggested that the aa-tRNA to eEF1A induces a conformational change, which allows efficient glucosylation by Lgt3.

To confirm the finding that aa-tRNA but not uncharged tRNA or any additional contaminant in the reaction mixture facilitates glucosylation, we monitored the dependence of the reaction on the addition of phenylalanine tRNA-synthetase (PheRS). Efficient Lgt-induced glucosylation of eEF1A depended on the presence of PheRS, suggesting the requirement of synthesis of Phe-tRNA_phe (Fig. 3A), whereas in the absence of PheRS, eEF1A glucosylation was hardly detectable. These data suggested that binding of aa-tRNA to eEF1A induces a conformational change, which allows efficient glucosylation by Lgt3.

Next, we tested whether catalytic amounts of aa-tRNA would be sufficient to induce glucosylation of eEF1A by Lgt3. The rate of glucosylation of yeast eEF1A increased with the addition of increasing amounts of HPLC-purified Phe-tRNA_phe and reached maximum velocity at 3 μM, the equimolar ratio of aa-tRNA and eEF1A (Fig. 3B). These results strongly suggested that the aa-tRNA to eEF1A ternary complex, rather than eEF1A alone, is the bona fide substrate of the Lgt.

To quantify the stimulatory effect of the ternary complex on Lgt3-catalyzed glucosylation of eEF1A, we compared initial velocities of the reaction with yeast eEF1A in the presence and absence of Phe-tRNA_phe and tRNA_phe (Fig. 4A). Only the eEF1A-GTP-Phe-tRNA_phe ternary complex was effectively modified. The kcat-value for glucosylation of yeast ternary complex was 150-fold higher compared to yeast eEF1A incubated with Phe-tRNA_phe and GDP (Table 1). Thus, the addition of aa-tRNA and GTP enabled a quantitative glucosylation of eEF1A. This was proven by glucosylation of the ternary complex of yeast eEF1A with unlabeled UDP-glucose followed by purification of the modified eEF1A by affinity chromatography and subsequent
second Lgt3-induced glucosylation with radiolabeled UDP-glucose (Fig. 4C).

To analyze the effect of Phe-tRNAPhe on Lgt-catalyzed glucosylation of mammalian eEF1A, we purified native eEF1A from mouse liver. The glucosylation of mouse eEF1A was even more prominent and enhanced 590-fold in the presence of aa-tRNA and GTP (Fig. 4B and Table 1).

Because the data emphasized the essential role of amino acid attached tRNA in enhancing glucosylation of eEF1A, we tested whether the effect could be reproduced in the presence of aa-tRNA other than Phe-tRNAPhe. We prepared His-tRNAPhe using recombinant histidyl-tRNA-synthetase, allowed ternary complex formation with yeast eEF1A and GTPyS and analyzed the complex in glucosyltransferase reactions with Lgt3. His-tRNAPhe stimulated glucosylation of yeast eEF1A very efficiently and the degree of stimulation was similar to that of Phe-tRNAPhe (Fig. 4D).

Next, we tested the other known Legionella glucosyltransferases (Lgt1 and 2) with the ternary complex of yeast eEF1A and determined the initial velocities with Phe-tRNAPhe in the presence of GTP or GDP. In line with Lgt3, the kcat-values for Lgt1 and 2 increased from 1.7±0.1 to 128.2±19.9 h−1 and 0.5±0.1 to 33.5±0.9 h−1, respectively, when yeast eEF1A-GTP-Phe-tRNAPhe ternary complex was used as a substrate (Table 1). These results support the notion that eEF1A ternary complex is the preferred substrate for Legionella glucosyltransferases.

full length eEF1A is essential for aa-tRNA-dependent stimulation of glucosylation

The crystal structure of the ternary complex of eEF1A with GTP and aa-tRNA is not known, but it is assumed that the interaction is similar to that found in the bacterial homolog complex [40]. The interaction surface of EF-Tu with aa-tRNA covers mainly domain II and domain III (Fig. 5A, right structure). The aminoacyl terminus of aa-tRNA is bound in between the G domain and domain II (Fig. 5A, red spheres) [41,42]. To test whether isolated fragments of eEF1A are sufficient to bind aa-
tRNA and thereby enhance its glucosylation we constructed several yeast eEF1A truncation mutants (Fig. 5A). The proteins p38 (eEF1A without domain III [aa1-349]), p29 (G domain [aa1-265]) and p5 (5 kDa peptide, comprising the helix-loop-helix region [aa29-73]) were purified and tested as substrates in the presence and absence of aa-tRNA (Fig. 5B). Except for the full-length eEF1A, only p38, which harbors the G domain and domain II, was more efficiently modified in the presence of aa-tRNA than in its absence (Fig. 5B insert), albeit to a much lower extent than the wild type eEF1A. Thus, full length eEF1A and an intact interface of the G domain and domain II seems to be necessary to allow aa-tRNA-dependent glucosylation. Belyi and co-workers demonstrated that in the absence of aa-tRNA, peptide fragments of eEF1A of a size down to 45 amino acid residues (aa29-72, fragment p5) or even a 10 amino acid fragment (aa50-59) were more efficiently glucosylated than purified full length eEF1A [36]. However, in direct comparison the ternary complex of eEF1A is more efficiently modified in the presence of aa-tRNA than the smaller fragment p5 (Fig. 5C) and is thus the preferred substrate of the reaction.

Aminoacyl-tRNA does not directly interact with Legionella glucosyltransferases

The fact that glucosylation of the eEF1A peptide fragments p5 or p29 were not influenced by the addition of aa-tRNA ruled out the possibility that aa-tRNA stimulated the glucosyltransferase directly (Fig. 5B). In addition, we were not able to precipitate [14C]Phe-tRNA^Phe^ by Lgt3 (not shown). Thus, we could not detect a direct effect of aa-tRNA on the enzyme activity in the absence of eEF1A.

The ternary complex formation is not generating additional acceptor sites for glucosylation

To exclude that aa-tRNA binding generated new glucosylation sites in eEF1A in addition to Ser-53, we tested the modification with a S53A mutation of eEF1A (Fig. 6). The mutation abolished the glucosylation by Lgt3 in the presence or absence of aa-tRNA. These results indicated that aa-tRNA binding does not unmask additional glycosyl acceptor sites apart from Ser-53.

Glucosylation does not impair the interaction between eEF1A and aa-tRNA

To study whether Lgt3-catalyzed glucosylation of eEF1A has any effects on the binding of aa-tRNA to eEF1A, we performed an aa-tRNA protection assay [33]. Here, eEF1A protects aa-tRNA from spontaneous deacylation within the ternary complex. We monitored deacylation with radiolabeled [14C]Phe-tRNA^Phe^ in a time course at 37°C. Non-hydrolyzed [14C]Phe-tRNA^Phe^ was quantified after filter-binding by scintillation counting (Fig. 7). Both native and glucosylated eEF1A protected aa-tRNA from hydrolysis, whereas non-complexed aa-tRNA was hydrolyzed almost completely after 60 min of incubation. Thus, glucosylation does not inhibit the formation of the ternary complex eEF1A with GTP and aa-tRNA.

Discussion

The members of the Legionella glucosyltransferase family (Lgt 1–3) modify eEF1A and potently inhibit eukaryotic protein synthesis in vitro. However, in contrast to the high biological activity of the enzymes, rate and efficiency of in vivo glucosylation of the purified eEF1A by recombinant Lgt’s are rather low. Notably, it was shown that a 45aa peptide, comprising aa29-72 of eEF1A, is more efficiently modified than full length eEF1A [36], suggesting that a specific conformation of eEF1A is essential for glucosylation.

Extensive search for additional factors in yeast cell lysate, which enhanced the efficiency of Lgt-catalyzed glucosylation of eEF1A, revealed non-proteinaceous cytosolic components, comprising aminooacyl-tRNA and GTP. A direct effect of aa-tRNA and GTP on the glucosyltransferase was excluded, because aa-tRNA was not able to stimulate Lgt-induced glucosylation of a 5 kDa-peptide substrate, consisting of the helix-loop-helix region of eEF1A. This indicates that the interaction of the full-length eEF1A is necessary for induction of the conformational state of eEF1A, which allows efficient glucosylation. Moreover, we observed that an equimolar ratio of aa-tRNA and eEF1A is required to obtain the maximum rate in glucosylation. This suggests that the ternary complex, consisting of eEF1A, GTP and aa-tRNA, is the

Figure 3. Aa-tRNA stimulates eEF1A glucosylation. (A) Time courses of the glucosylation of yeast eEF1A (yEF1A) with Lgt3 were performed in the presence of yeast tRNA (10 μM) and 10 μM UDP-[14C]glucose (triangles). Phe-tRNA synthetase was added at time point 10 mM PEP, 0.1 mg/ml pyruvate kinase and 10
doi:10.1371/journal.pone.0029525.g003

Lgt3 (5 nM) was conducted with increasing concentrations of HPLC-purified [14C]Phe-tRNAPhe. Initial glucosylation rates were determined of three independent experiments. (B) Glucosylation of yEF1A (3 μM) by Lgt3 (5 nM) was conducted with increasing concentrations of HPLC-purified [14C]Phe-tRNA^Phe^, Initial glucosylation rates were determined after incubation for 10 min at 30°C in the presence of 50 μM GTP; 50 mM PEP, 0.1 mg/ml pyruvate kinase and 10 μM UDP-[14C]glucosylase as the donor substrate. Radiolabeled aa-tRNA could be distinguished from [14C]-glucosylated yEF1A by separation of the products by SDS-PAGE. Data shown represent velocities of yEF1A glucosylation and are given as means (±SD) of three independent experiments. doi:10.1371/journal.pone.0029525.g003
Competent substrate for Lgt's. Kinetic measurements of glucosylation of yeast and mammalian EF1A by Lgt3 revealed that $k_{\text{cat}}$ values increased 150 to 580-fold in the presence of aa-tRNA and GTP.

The interaction of the prokaryotic parologue EF-Tu with aa-tRNA is well studied and its affinity seems to be similar for all aa-tRNAs. This general affinity was shown to depend on both sides, the nature of the esterified amino acid and the tRNA body, resulting in comparable affinity by “thermodynamic compensation” [43–48]. Our results highlight the importance of amino acids attached to tRNA, because uncharged tRNA was ineffective in stimulation of eEF1A glucosylation. Using histidyl-tRNA and phenylalanyl-tRNA, respectively, in complex with yeast eEF1A and GTP, we showed that the attached individual amino acid and...
The difference in the acceptor stem region, which is elongated by one base pair in the case of His-tRNA<sup>His</sup>, is not crucial for glucosylation. Of course, we cannot exclude that other types of aa-tRNA show specific effects on activation of glucosylation not observed with Phe-tRNA<sup>Phe</sup> or His-tRNA<sup>His</sup>.

Gromadski et al. investigated the affinity of Phe-tRNA<sup>Phe</sup> for eEF1A-GTP and obtained a <i>k<sub>cat</sub></i>-value of 3 nM, whereas binding of Phe-tRNA<sup>Phe</sup> to the GDP-bound eEF1A was not measurable [33]. The affinity of GTP or GDP to eEF1A was comparable and their binding was suggested not to induce major structural rearrangements at least in the structural complex with eEF1B [39]. These observations are consistent with the glucosylation behavior of Lgt3. Neither the GDP- nor the GDP-bound form of yeast eEF1A was an efficient substrate for glucosylation, indicating failure to generate the correct target conformation. The same was true for uncharged tRNA, which reportedly has a very low affinity to GTP-bound eEF1A [33]. Thus, the mixture of eEF1A, GTP or GDP and uncharged tRNA was not efficiently modified by Lgt3.

As our results demonstrate that addition of aa-tRNA and GTP (or GTPS) to <i>in vitro</i> enzymatic assays largely increases the rate and efficiency of glucosylation of eEF1A by Lgt’s, it is likely that major conformational rearrangements of eEF1A occur upon the binding of aa-tRNA and GTP, which form a stable ternary complex (eEF1A-GTP(aa-tRNA)). We suggest that such an interaction induces structural changes in the G domain, particularly in the helix-loop-helix region, harboring acceptor amino acid Ser-53, which allow efficient transfer of the glucose moiety to the substrate.

Table 1. <i>k<sub>cat</sub></i>-values for glucosylation of eEF1A ternary complex by Lgt’s.

| Transferase | Substrate          | <i>k<sub>cat</sub></i> [h<sup>-1</sup>] |
|-------------|--------------------|----------------------------------------|
| Lgt3        | yEF1A-GTP-Phe-tRNA<sup>Phe</sup> | 381.7 ± 26.7                           |
| Lgt3        | yEF1A-GTP-Phe-tRNA<sup>Phe</sup> | 2.5 ± 0.1                              |
| Lgt3        | mEF1A-GTP-Phe-tRNA<sup>Phe</sup> | 340.5 ± 19.5                           |
| Lgt3        | mEF1A-GDP-Phe-tRNA<sup>Phe</sup> | 0.6 ± 0.1                              |
| Lgt1        | yEF1A-GTP-Phe-tRNA<sup>Phe</sup> | 128.2 ± 19.9                           |
| Lgt1        | yEF1A-GTP-Phe-tRNA<sup>Phe</sup> | 1.7 ± 0.1                              |
| Lgt2        | yEF1A-GTP-Phe-tRNA<sup>Phe</sup> | 33.5 ± 0.9                             |
| Lgt2        | yEF1A-GDP-Phe-tRNA<sup>Phe</sup> | 0.5 ± 0.1                              |

Yeast eEF1A (yEF1A) and mouse eEF1A (mEF1A) were incubated for 10 min with an equimolar concentration of HPLC-purified Phe-tRNA<sup>Phe</sup> and GTP-S or GDP-S (50 μM) as indicated. Afterwards the complexes were subjected to in vitro glucosyltransferase reactions with UDP [<sup>14</sup>C]glucose (10 μM) and 5 nM Lgt1, 2 and 3. The data were autoradiographically quantified using ImageQuant. Data are given as the mean (±SD) of triplicates of 5 min time points.

doi:10.1371/journal.pone.0029525.t001

<sup>The difference in the acceptor stem region, which is elongated by one base pair in the case of His-tRNA<sup>His</sup>, is not crucial for glucosylation. Of course, we cannot exclude that other types of aa-tRNA show specific effects on activation of glucosylation not observed with Phe-tRNA<sup>Phe</sup> or His-tRNA<sup>His</sup>.</sup>

the functional consequences of eEF1A glucosylation and inhibition of protein synthesis during the infection process of <i>Legionella</i> is not completely understood. It might be that inhibition of protein synthesis is essential for <i>Legionella</i>-induced cell death and pathogen release after replication [29,31]. Another possibility is the involvement of Lgt’s in fine-tuning of the host metabolism to optimize the host environment for replication. Also protein synthesis inhibition might cause an altered host cell defence mechanism by reduced or elevated factors of the innate immune system [32,50] or an altered host stress response [35,51]. Moreover, modification of the non-canonical functions of eEF1A (e.g. influence on the actin cytoskeleton or on subcellular organization [34]), which are are still controversially discussed, might also play an important role in the infection process. In conclusion, our data suggest that full length eEF1A binds aa-tRNA and GTP to form the competent substrate conformation required for glucosylation by Lgt’s. By selecting the ternary complex of eEF1A, aa-tRNA and GTP as the preferred substrate for Lgt-induced modification within the abundant pool of eEF1A inside cells, the bacterial effectors increase their efficiency to inhibit protein synthesis of their hosts.

Materials and Methods

Materials and plasmids

<i>Escherichia coli</i> strain BL21 (DE3) and <i>Saccharomyces cerevisiae</i> AH272-3α (ura3 leu2 his3 trp1 ade2) were used for protein expression. <i>L. pneumophila</i> serogroup 1 Philadelphia I and the strain <i>L. pneumophila</i> AM101 deficient in all <i>lgt</i> genes (<i>Δlgt1</i>, <i>Δlgt3</i>, <i>Δlgt2::kan</i>) were used for infection studies. The AM101 strain was kindly provided by Dr. Craig Roy (Yale University, New Haven, USA). Murine RAW 264.7 macrophages were used for infection studies. Expression vector pGEX-4T was from GE Healthcare (Freiburg, Germany), pET28a vector from Novagen (Madison, WI), pBC KS (+) and pBluescript KS (+) vectors were from Stratagene (Waldbraun, Germany). For expression of yeast proteins pRS313, pRS423, and YCpLac22 vectors were used. DNA-modifying enzymes were purchased from Fermentas (St. Leon-Rot, Germany). UDP-[<sup>14</sup>C]glucose was from American Radiolabeled Chemicals (St. Louis, USA). PfII Turbo DNA Polymerase was from Stratagene and Phusion<sup>TM</sup>, and High-Fidelity DNA Polymerase from New England Biolabs (Ipswich, MA). All other reagents were of analytical grade and purchased from commercial sources.

Cloning of genes for bacterial expression

The genes <i>lgt1</i> (lpg1368), <i>lgt2</i> (lpg2862), and <i>lgt3</i> (lpg1488) were amplified with PfII Turbo from the genomic DNA of <i>L. pneumophila</i> strain Philadelphia-I and cloned into a modified pET28a TEV as published [27]. The pET2-403G (p5) plasmid, coding for GST-fused 45aa catalytic fragment of Tef1p was kindly provided by Dr. Craig Roy (Yale University, New Haven, USA). Murine RAW 264.7 macrophages were used for infection studies. Expression vector pGEX-4T was from GE Healthcare (Freiburg, Germany), pET28a vector from Novagen (Madison, WI), pBC KS (+) and pBluescript KS (+) vectors were from Stratagene (Waldbraun, Germany). For expression of yeast proteins pRS313, pRS423, and YCpLac22 vectors were used. DNA-modifying enzymes were purchased from Fermentas (St. Leon-Rot, Germany). UDP-[<sup>14</sup>C]glucose was from American Radiolabeled Chemicals (St. Louis, USA). PfII Turbo DNA Polymerase was from Stratagene and Phusion<sup>TM</sup>, and High-Fidelity DNA Polymerase from New England Biolabs (Ipswich, MA). All other reagents were of analytical grade and purchased from commercial sources.

Cloning of genes for yeast expression

Initially, the coding sequence of yeast eEF1A with ~500 nts upstream and downstream regions was amplified from <i>S. cerevisiae</i> chromosomal DNA using primers #518/#492 (Table S1), the product digested with BamHI/SalI restriction endonucleases and ligated into similarly digested pRS313 [32], producing plasmid
Figure 5. Models of eEF1A constructs and activity of Lgt’s in glucosylation of eEF1A fragments. (A) Schematic representation of the eEF1A truncations used (upper panel). Lower panel: Structural models deduced from the crystal structure of eEF1A in complex with eEF1B (pdb 1UF). For visualization of the region of aminoacyl-tRNA binding the crystal structure of the ternary complex of EF-Tu•GTP-Phe-tRNAPhe (pdb 1TTT) is depicted on the right. The GTPase domain (G domain) is shaded in orange, domain II in blue, domain III in green, and tRNA is shown in brown. The aminoacyl residue of aa-tRNA located between the G domain and domain II is shown as red spheres. GDP or GTP is depicted as black sticks. The position of glucosyl acceptor serine 53 is shown in red and marked with arrowheads. The figures were prepared using PyMOL (www.pymol.org). (B) Glucosylation of different truncation fragments of yeast eEF1A (yEF1A) (3 μM) was performed with Lgt3 (140 nM) in the presence of Phe-tRNAPhe or uncharged tRNAPhe (each 1 μM), respectively. Constructs used: p38 represent eEF1A without domain III (aa1-349), p29 harbors the G domain (aa1-265), and p5 is a 5 kDa-peptide, comprising the helix-loop-helix region (aa29-73) of yEF1A. Glucosylation was performed under standard conditions for 15 min at 30°C. The insert shows the induction of Lgt3-catalyzed glucosylation of the fragments by Phe-tRNAPhe. (C) Time courses of in vitro glucosylation of yEF1A in complex with GTP and Phe-tRNAPhe (open circles), the 45 amino acid fragment of yEF1A p5 (filled squares), yEF1A (filled circles), and yEF1A with uncharged tRNAPhe (open triangles) by Lgt3. All data given represent means (±SD) of three independent experiments. doi:10.1371/journal.pone.0029525.g005
A C-terminal 6xHis-tag was inserted by amplification of the corresponding sequences from yeast chromosomal DNA with primers #649/#650 and #651/#492, digesting the products with NcoI/EcoRI and EcoRI/SalI and subsequently ligating them sequentially into pET28a, thus generating a plasmid p672. The final construct, encoding a C-terminally 6xHis-tagged yeast eEF1A was produced by replacing a part of p572 with the NcoI/SalI fragment from p672 thus generating plasmid p689. To clone the gene coding for the C-terminally 6-His-tagged G domain, the gene of yeast eEF1A with upstream and downstream regions (see cloning p572) was subcloned into YCpLac22 plasmid [53] using BamHI/Sall restriction sites (plasmid p553). Then, the SacI/XbaI fragment containing coding sequence of the G domain with upstream promoter region was ligated into the pBluescript KS (+) vector (p681). To attach a 6xHis-tag, the G domain-coding sequence was cut out from p681 using SacI/HindIII and ligated into pET28b (p682). Finally, the plasmid was amplified with the primers #16/#660, the amplicon digested with SacI/Sall and ligated into pRS423 vector [32] to generate the plasmid p710. To construct the C-terminally 6xHis-tagged yeast eEF1A S53A mutant, the region coding for the Ser-53-containing peptide was excised out of p553 with endonucleases SacI/ClaI and ligated into the pBG KS (+) vector, generating plasmid p574. QuickChange (Stratagene) site-directed mutagenesis technology was applied to the plasmid p689 (C-terminally 6xHis-tagged yeast eEF1A, see above) to substitute the Ser-53 by Ala using the primers #542/#543, generating the S53A substitution (plasmid p575). Subsequently, wild type coding region in the plasmid p689 (C-terminally 6xHis-tagged yeast eEF1A, see above) was substituted with the mutated sequence using SacI/ClaI insert of p575, to obtain the plasmid p726. For yeast transformation, standard genetic techniques were applied [54].

Purification of recombinant proteins

E. coli BL21(DE3) transformed with the desired plasmid was grown in the LB broth supplemented with ampicillin or kanamycin on a shaker at 37°C until A600 = 0.8. Protein extracts from the pET28-based plasmids were induced by 1 mM isopropyl-β-D-thiogalactopyranoside (Roth, Karlsruhe, Germany) for 4–5 h at 22°C, and for pGEX-based constructs with 0.2 mM isopropyl-β-D-thiogalactopyranoside at 37°C for 3 h.

Bacterial cells were harvested by centrifugation at 6,000 × g for 15 min, resuspended in lysis buffer (20 mM Tris–HCl (pH 7.4), 150 mM NaCl, 25 mM imidazole, 30 μg/ml DNase I, 10 mM β-mercaptoethanol, 1 mg/ml lysozyme and Proteinase Inhibitor Cocktail (Roche)) and lysed by French press or sonication. The cleared lysate was subjected to chromatography on a glutathione-Sepharose Fast Flow or nickel-equilibrated chelating Sepharose Fast Flow column according to the manufacturer’s instructions (GE Healthcare). Bound proteins were eluted with 10 mM reduced glutathione, 0.5 M imidazole or thrombin treatment, depending on the construct used.

For the production of recombinant yeast 6xHis-containing protein, S. cerevisiae was grown overnight in a medium containing 0.62% yeast nitrogen base with ammonium sulfate without amino acids (Difco, USA), 100 μg/ml of L-leucine and 20 μg/ml of each L-tryptophan, uracil, and adenine, and 2% glucose. Yeast cells were disrupted by Oscillating Mill MM 400 (Retsch, Germany). Clear extracts were subjected to HisTrap FF chromatography using Akta Purifier (GE Healthcare). Yeast eEF1A (yEF1A) and mammalian eEF1A (mEF1A) were purified based on their interaction with His-tagged yEF1Bα as described previously [38]. In brief, yEF1Bα expressed in E. coli and purified on a HiTrap HP column was used to pulldown eEF1A from the commercial baker’s yeast lysate or mouse liver tissue homogenate. The complex was applied onto a HiTrap HP column with eEF1A lysis buffer (100 mM Tris–HCl pH 7.6 at 6°C, 200 mM KCl, 5 mM MgCl2, 10% glycerol, 0.5 mM, β-mercaptoethanol, 20 mM imidazole, 0.1 mM PMSF, and protease inhibitor cocktail). The eEF1A-EF1Bα complex was eluted with a linear gradient of 20 to 250 mM imidazole. eEF1A was released from the complex by incubation with 100 μM GDP and applied onto Mono Q column (GE Healthcare, Freiburg, Germany) followed by further purification on a Resource S column (GE Healthcare) and dialysis against a final storage buffer (20 mM Tris–HCl (pH 7.6), 130 mM KCl, 5 mM MgCl2, 0.5 mM dithiothreitol, 15 μM GDP, and 25% glycerol). Glucosylated eEF1A was purified similarly.

Aminoacyl-tRNA synthesis

Phe-tRNA was obtained by incubation of 5 μM purified yeast tRNA (Sigma, St. Louis, USA) and yeast phenylalanyl-
tRNA synthetase (PheRS) (750 nM) [55] with 250 μM [14C]-phenylalanine (868 dpm/pmol), or 100 μM unlabeled phenylalanine in charging buffer (20 mM Hepes/KOH (pH 7.3), 2.5 mM spermidine trihydrochloride, 1 mM ATP, 5 mM MgCl₂, 1 mM DTT, and 100 mM NH₄Cl) for 20 min at 37°C. The extent of aminoacylation was determined by scintillation counting after trichloroacetic acid precipitation and filtration through GF/C filters. HPLC purified [14C]Phe-tRNAph was prepared as described [56]. Histidyl-tRNAHis was prepared by charging yeast tRNAph in the yeast RNA mixture (Sigma) with histidyl-tRNA synthetase (HisRS) (MY Biosource, San Diego, USA). Ternary complex was formed after incubation of the components for 10 min at room temperature in the presence of 75 μM GTP, 0.1 mg/ml pyruvate kinase and 10 mM phosphoenolpyruvate. After ternary complex formation of yeast eEF1A, GTP and His-tRNAHis, the remaining uncharged tRNA was digested with RNase A for 10 min at 4°C prior to glucosylation reaction.

**Glucosyltransferase assay**

Yeast cell lysate used as crude substrate for Lgt was prepared by lysis of a pellet of yeast culture with an Oscillating Mill MM 400 (Retsch, Germany). Glucosylation was performed with 140 nM (if not otherwise noted) recombinant His-tagged Lgt1, 2, and 3 and crude eukaryotic cell extract or recombinant substrates (3 μM) in a total volume of 20 μl. The standard reaction proceeded at 30°C for 15 min in 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM MnCl₂, and 10 μM UDP-[14C]glucose. The reaction was stopped by the addition of SDS-sample buffer and heating at 95°C for 5 min. Subsequently, samples were subjected to SDS-PAGE. Proteins were stained with Coomassie and radiolabeled bands were analyzed by PhosphorImaging and quantification with ImageQuant 5.2 (GE Healthcare, Freiburg, Germany).

**Aa-tRNA protection assay**

Yeast eEF1A (20 μM) was glucosylated by 5 μM Lgt3 for 5 min at 37°C in the presence of 1 mM UDP-glucose, GTP, tRNAph, phenylalanine, PheRS, phosphoenolpyruvate, and pyruvate kinase as described above. Modified and unmodified yeast eEF1A was purified from TEV-cleaved Lgt3 by His-tagging affinity chromatography (see Purification of Recombinant Proteins). The formation of the ternary complex was obtained by incubation of 3 μM glucosylated or non-glucosylated yeast eEF1A with 1 μM [14C]Phe-tRNAph from yeast, 1 mM GTP, 3 mM phosphoenolpyruvate, 1 mM ATP, 7 mM MgCl₂ and 1% of pyruvate kinase in 70 μl of TAKM7 buffer (50 mM Tris-HCl (pH 7.5), 70 mM NH₄Cl, 7 mM MgCl₂ and 30 mM KCl) as described [33]. The reaction was carried out at 37°C and at various time points 2×3 μl of the reaction solution was precipitated by 10% trichloroacetic acid and transferred onto nitrocellulose filters. After washing with 5% trichloroacetic acid non-hydrolyzed [14C]Phe-tRNAph was measured by scintillation counting.

**Cell culture**

Raw 264.7 macrophages were cultivated in Dulbecco's MEM modified Eagles medium supplemented with 10% fetal calf serum (FCS) and penicillin/streptomycin (Biochrom, Berlin, Germany). Cell lines were cultured at 37°C in 5% CO₂. The Legionella strains were grown on charcoal-yeast-extract agar plates [31] or PP3# liquid medium (per liter: 15 g proteose peptone no. 3 (Difco), 10 g ACES-buffer, 0.4 g L-cysteine H₂O, 1 g 2-ketogluatrate, (pH 6.9)). Kanamycin 25 μg/ml was applied where necessary.

**Isolation of in vivo glucosylated eEF1A**

6x100 mm dishes RAW 264.7 macrophages (80% confluence) were incubated for 1 h in DMEM-medium without additives. Legionella strains were cultivated on charcoal plates and liquid medium to an OD₆⁰₀ of 2.0. Subsequently, RAW macrophages were infected with L. pneumophila strains indicated (multiplicity of infection = 100). After incubation for 5 h under cell culture conditions, macrophages were washed extensively and scraped off with lysis buffer (50 mM Tris (pH 7.4), 100 mM NaCl, 1 mM MgCl₂, 1 mM PMSF and complete protease inhibitor mix (Roche)) and lysed by 10 strokes with a 1 ml syringe equipped with a G26 needle. After centrifugation (17,900 x g, 10 min), the post-nuclear supernatant was incubated with 100 μg His-tagged eEF1Bz for 15 min on ice followed by Ni²⁺-affinity chromatography. After elution with 500 mM imidazole, proteins were reduced by diithiothreitol treatment, alkylated with iodoacetamide, and separated by 12.5% SDS-PAGE. The corresponding bands of eEF1A were excised and analyzed by mass spectrometry.

**LC-MS/MS analysis**

For in-gel digestion the excised gel bands were destained with 30% ACN, shrunk with 100% ACN, and dried in a Vacuum Concentrator (Concentrator 5301, Eppendorf, Hamburg, Germany). Digests with chymotrypsin was performed overnight at 25°C in 0.1 M NH₄HCO₃ (pH 8). About 0.1 μg of protease was used for one gel band. Peptides were extracted from the gel slices with 5% formic acid. All LC-MS/MS analyses were performed on a Q-TOF mass spectrometer (Agilent 6520, Agilent Technologies) coupled to a 1200 Agilent nanoflow system via a HPLC-Chip cube ESI interface. Peptides were separated on a HPLC-Chip with an analytical column of 75 μm i.d. and 150 mm length and a 40-nL trap column, both packed with Zorbax 300SB C-18 (5 μm particle size). Peptides were eluted with a linear acetonitrile gradient with 1%/min at a flow rate of 300 nl/min starting with 3% acetonitrile. The Q-TOF was operated in the 2 GHz extended dynamic range mode. MS/MS analyses were performed using data-dependent acquisition mode. After a MS scan (2 spectra/s), a maximum of three peptides were selected for MS/MS (2 spectra/s). Singly charged precursor ions were excluded from selection. Internal calibration was applied. Mascot Distiller 2.3 was used for raw data processing and for generating peak lists, essentially with standard settings for the Agilent Q-TOF. Mascot Server 2.3 was used for database searching with the following parameters: peptide mass tolerance: 20 ppm, MS/MS mass tolerance: 0.05 Da, enzyme: chymotrypsin with 2 uncleaved sites allowed, variable modifications: Carbamidomethyl (C), Gln->pyroGlu (N-term), Q, oxidation (M) and Hexose (ST). For protein identification SwissProt protein database was used.

**Supporting Information**

**Table S1 Oligonucleotides, used for cloning of yeast eEF1A constructs.**

(DOC)

**Acknowledgments**

We thank Peter Gebhardt and Stephanie Lamer for excellent technical assistance.

**Author Contributions**

Conceived and designed the experiments: TT TJ KA. Performed the experiments: TT TJ YB AS. Analyzed the data: TT TJ CP AS KA. Contributed reagents/materials/analysis tools: SR CK MR. Wrote the paper: TJ KA.
Legionella Lgt's Glucosylate aa-tRNA-Charged eEF1A

References

1. Fraser DW, Tsai TR, Orenstein W, Parkin WE, Beecham HJ, et al. (1977) Legionnaires' disease: description of an epidemic of pneumonia. N Engl J Med 297: 1189–1197.
2. Harb OS, Gao LY, Abu KY (2000) From protozoa to mammalian cells: a new paradigm in the life cycle of intracellular bacterial pathogens. Environ Microbiol 2: 231–265.
3. Huber RR, Yu VL, Woo AH (1986) Mode of transmission of Legionella pneumophila. A critical review. Arch Intern Med 146: 1607–1612.
4. Isberg RR, O'Connor TJ, Heideman M (2009) The Legionella pneumophila replication vacuole: making a nice niche inside host cells. Nat Rev Microbiol 7: 13–24.
5. Segal G, Feldman M, Zasman T (2005) The Icm/Dot type-IV secretion systems of Legionella pneumophila and Cardinium bartonii. FEMS Microbiol Rev 29: 65–81.
6. Segal G, Porell M, Shuman HA (1998) Host cell killing and bacterial conjugation require overlapping sets of genes within a 22 kb region of the Legionella pneumophila genome. Proc Natl Acad Sci U S A 95: 1669–1674.
7. Vogel JP, Andrews HL, Wong SK, Isberg RR (1998) Conjugative transfer by the virulence system of Legionella pneumophila. Science 279: 873–876.
8. Hubber A, Roy CR (2010) Modulation of host cell function by Legionella pneumophila type IV effectors. Annu Rev Cell Dev Biol 26: 261–293.
9. Ninio S, Roy CR (2007) Effector proteins translocated by Legionella pneumophila: strength in numbers. Trends Microbiol 15: 372–380.
10. Enominger AW, Isberg RR (2009) Legionella pneumophila Dot/Icm translocated substrates: a sum of parts. Curr Opin Microbiol 12: 67–73.
11. Luo ZQ, Isberg RR (2004) Multiple substrates of the Dot/Icm translocated substrates: a sum of parts. Curr Opin Microbiol 12: 67–73.
12. Heideman M, Chen EJ, Moy MY, Isberg RR (2009) Large-scale identification of Legionella pneumophila Dot/Icm system identified by interbacterial protein transfer. Proc Natl Acad Sci U S A 106: 241–246.
13. de Felipe KS, Glover FT, Charpentier X, Anderson OR, Reyes M, et al. (2008) Legionella eukaryote-like type IV substrates interfere with organelle trafficking. PLoS Pathog 4: e1000117.
14. Nagai H, Cambreman ED, Kagan JC, Amor JC, Kahn RA, et al. (2005) A C-terminal translocation signal required for Dot/Icm-dependent delivery of the Legionella Ralf protein to host cells. Proc Natl Acad Sci U S A 102: 826–831.
15. Machner MP, Isberg RR (2007) A bifunctional bacterial protein links GDI displacement to Rabl activation. Science 318: 974–977.
16. Murata T, Delprato A, Ingmundson A, Toomre DK, Lambricht DG, et al. (2006) The Legionella pneumophila effector protein DrrA is a Rab1 glucosyl-nucleotide-exchange factor. Nat Cell Biol 8: 971–977.
17. Zhi W, Barga S, Tan Y, Zheng C, Stephenson R, et al. (2011) Comprehensive identification of protein substrates of the Dot/Icm type IV transporter of Legionella pneumophila. PLoS One 6: e17638.
18. Ingmundson A, Delprato A, Lambright DG, Roy CR (2007) Legionella pneumophila type IV effectors. Annu Rev Cell Dev Biol 23: 321–331.
19. Nagai H, Kuroha K, Saito K, Ito K, et al. (2010) Structural basis of elongation factor 1A inhibition by a bacterial effectors that inhibit host protein synthesis are critical for induction of the innate immune response to virulent Legionella pneumophila. PLoS Pathog 7: e1001289.
20. Gromadski KB, Schummer T, Stromgaard A, Knudsen CR, Kinzy TG, et al. (2007) Kinetics of the interactions between yeast elongation factors 1A and 1Balpha, gamma nucleotides, and aminocyl-tRNA. J Biol Chem 282: 35629–35637.
21. Mateyk MK, Kinzy TG (2010) eEF1A: thinking outside the ribosome. J Biol Chem 285: 21289–21213.
22. Shmavony I, Ivanikovs M, Kandel ES, Gershon D, Nueller E (2006) RNA-mediated response to heat shock in mammalian cells. Nature 440: 536–560.
23. Belyi Y, Stahl M, Sovkova I, Kaden P, Luy B, et al. (2009) Region of elongation factor 1A involved in substrate recognition by Legionella pneumophila glucosyltransferase LGT1-identification of LGT1 as a retaining glucosyltransferase. J Biol Chem 284: 20167–20174.
24. Ivanov SS, Roy CR (2009) Modulation of ubiquitin dynamics and suppression of DfT formation by the Legionella pneumophila Dot/Icm system. Cell Microbiol 11: 261–278.
25. Nissen P, Kjeldgaard M, Stromgaard A, Knudsen CR, Nyborg J, et al. (1995) Crystal structure of the ternary complex of the eEF1A and eEF1B alpha. Acta Crystallogr D Biol Crystallogr 51: 159–161.
26. Andersson GR, Valente L, Pedersen I, Kinzy TG, Nyborg J (2001) Crystal structures of nucleotide exchange intermediates in the eEF1A-eEF1Balpha complex. Nat Struct Biol 8: 531–534.
27. Nissen P, Kjeldgaard M, Thirup S, colleagues G, Katalinina L, et al. (1995) Crystal structure of the ternary complex of Phe-tRNAPh and EF-Tu, and a GTP analog. Science 270: 1464–1472.
28. Belyi Y, Stahl M, Sovkova I, Kaden P, Luy B, et al. (2009) Region of elongation factor 1A involved in substrate recognition by Legionella pneumophila glucosyltransferase LGT1-identification of LGT1 as a retaining glucosyltransferase. J Biol Chem 284: 20167–20174.
29. Belyi Y, Schummer T, Stromgaard A, Knudsen CR, Kinzy TG, et al. (2007) Kinetics of the interactions between yeast elongation factors 1A and 1Balpha, gamma nucleotides, and aminocyl-tRNA. J Biol Chem 282: 35629–35637.
30. Bancroft AR, Kuroha K, Saito K, Ito K, et al. (2010) Structural basis of elongation factor 1A inhibition by a bacterial effectors that inhibit host protein synthesis are critical for induction of the innate immune response to virulent Legionella pneumophila. PLoS Pathog 7: e1001289.
31. Gromadski KB, Schummer T, Stromgaard A, Knudsen CR, Kinzy TG, et al. (2007) Kinetics of the interactions between yeast elongation factors 1A and 1Balpha, gamma nucleotides, and aminocyl-tRNA. J Biol Chem 282: 35629–35637.
32. Mateyk MK, Kinzy TG (2010) eEF1A: thinking outside the ribosome. J Biol Chem 285: 21289–21213.
33. Shmavony I, Ivanikovs M, Kandel ES, Gershon D, Nueller E (2006) RNA-mediated response to heat shock in mammalian cells. Nature 440: 536–560.
34. Belyi Y, Stahl M, Sovkova I, Kaden P, Luy B, et al. (2009) Region of elongation factor 1A involved in substrate recognition by Legionella pneumophila glucosyltransferase LGT1-identification of LGT1 as a retaining glucosyltransferase. J Biol Chem 284: 20167–20174.
35. Ivanov SS, Roy CR (2009) Modulation of ubiquitin dynamics and suppression of DfT formation by the Legionella pneumophila Dot/Icm system. Cell Microbiol 11: 261–278.
36. Pedersen L, Andersson GR, Knudsen CR, Kinzy TG, Nyborg J (2001) Crystal structures of the yeast elongation factor complex eEF1A-eEF1B alpha. Acta Crystallogr D Biol Crystallogr 57: 159–161.
37. Andersson GR, Valente L, Pedersen I, Kinzy TG, Nyborg J (2001) Crystal structures of nucleotide exchange intermediates in the eEF1A-eEF1Balpha complex. Nat Struct Biol 8: 531–534.
38. Nissen P, Kjeldgaard M, Thirup S, colleagues G, Katalinina L, et al. (1995) Crystal structure of the ternary complex of Phe-tRNAPh and EF-Tu, and a GTP analog. Science 270: 1464–1472.
39. Belyi Y, Schummer T, Stromgaard A, Knudsen CR, Kinzy TG, et al. (2007) Kinetics of the interactions between yeast elongation factors 1A and 1Balpha, gamma nucleotides, and aminocyl-tRNA. J Biol Chem 282: 35629–35637.
40. Bancroft AR, Kuroha K, Saito K, Ito K, et al. (2010) Structural basis of elongation factor 1A inhibition by a bacterial effectors that inhibit host protein synthesis are critical for induction of the innate immune response to virulent Legionella pneumophila. PLoS Pathog 7: e1001289.
41. Gromadski KB, Schummer T, Stromgaard A, Knudsen CR, Kinzy TG, et al. (2007) Kinetics of the interactions between yeast elongation factors 1A and 1Balpha, gamma nucleotides, and aminocyl-tRNA. J Biol Chem 282: 35629–35637.
42. Bancroft AR, Kuroha K, Saito K, Ito K, et al. (2010) Structural basis of elongation factor 1A inhibition by a bacterial effectors that inhibit host protein synthesis are critical for induction of the innate immune response to virulent Legionella pneumophila. PLoS Pathog 7: e1001289.